A risk model to predict 2-year survival after video-assisted thoracoscopic surgery lobectomy for non-small-cell lung cancer.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
01 04 2020
Historique:
received: 22 07 2019
revised: 19 09 2019
accepted: 02 10 2019
pubmed: 14 11 2019
medline: 22 6 2021
entrez: 14 11 2019
Statut: ppublish

Résumé

We sought to identify the risk factors associated with mortality post-video-assisted thoracoscopic surgery (VATS) lobectomy over a 2-year period. Analysis was performed using a sample from an institutionally maintained database. All lobectomies for non-small-cell lung cancer from April 2014 to March 2018 started with VATS approach and with a complete follow-up were included (n = 732). Several clinical variables were screened using the Cox univariate analysis for their association with 2-year survival. Those with a P-value <0.1 were included in a Cox proportional hazard model. After multivariable analysis, the following variables showed significant association with 2-year survival: age >75 [hazard ratio (HR) 1.527, P = 0.043], carbon monoxide lung diffusion capacity <70 (HR 1.474, P = 0.061), body mass index (BMI) <18.5 (HR 2.628, P = 0.012), American Society of Anesthesiologist Physical Status >2 (HR 1.518, P = 0.047), performance status >1 (HR 1.822, P = 0.032) and male gender (HR 2.700, P < 0.001). A score of 2 was assigned to the male gender and BMI <18.5, with all other variables assigned a score of 1. Each patient was scored and placed into their risk class. A Kaplan-Meier estimate for 2-year survival was calculated for each class. These were collapsed into the following 3 classes of risk based on their similar 2-year survival: class A (score 0) 97%, 95% CI 88-99, class B (score 1-3) 84%, 95% CI 80-88, class C (score > 3) 66%, 95% CI 57-74. Our scoring system can serve as an adjunct to a clinician's experience in risk-stratifying patients during multidisciplinary tumour board discussion and the shared decision-making process.

Identifiants

pubmed: 31722375
pii: 5625090
doi: 10.1093/ejcts/ezz304
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

781-787

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Hui Xian Tan (HX)

Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK.

Benjamin Cooper Drake (BC)

Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK.

Nilanjan Chaudhuri (N)

Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK.

Manos Kefaloyannis (M)

Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK.

Richard Milton (R)

Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK.

Kostas Papagiannopoulos (K)

Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK.

Peter Tcherveniakov (P)

Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK.

Alessandro Brunelli (A)

Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH